31 related articles for article (PubMed ID: 3117570)
1. Diagnostic and Prognostic Value of PACAP in Multiple Myeloma.
Tóth T; Alizadeh H; Polgár B; Csalódi R; Reglődi D; Tamás A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445974
[TBL] [Abstract][Full Text] [Related]
2. Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: A possible prognostic marker.
Zahran AM; Nafady-Hego H; Moeen SM; Eltyb HA; Wahman MM; Nafady A
Afr J Lab Med; 2021; 10(1):129. PubMed ID: 34522628
[TBL] [Abstract][Full Text] [Related]
3. Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Cona MS; Lecchi M; Cresta S; Damian S; Del Vecchio M; Necchi A; Poggi MM; Raggi D; Randon G; Ratta R; Signorelli D; Vernieri C; de Braud F; Verderio P; Di Nicola M
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30769874
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.
Kiba T; Ito T; Nakashima T; Okikawa Y; Kido M; Kimura A; Kameda K; Miyamae F; Tanaka S; Atsumi M; Sumitani Y; Shitakubo Y; Niimi H
BMC Cancer; 2014 Jun; 14():462. PubMed ID: 24952705
[TBL] [Abstract][Full Text] [Related]
5. Serum Level of Lactate Dehydrogenase is a Useful Clinical Marker to Monitor Progressive Multiple Myeloma Diseases: A Case Report.
Teke HÜ; Başak M; Teke D; Kanbay M
Turk J Haematol; 2014 Mar; 31(1):84-7. PubMed ID: 24764735
[TBL] [Abstract][Full Text] [Related]
6. [Biochemical and immunological findings of multiple myeloma].
Asaoku H
Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
Diem H; Fateh-Moghadam A; Lamerz R
Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
[TBL] [Abstract][Full Text] [Related]
8. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.
Barlogie B; Smallwood L; Smith T; Alexanian R
Ann Intern Med; 1989 Apr; 110(7):521-5. PubMed ID: 2647015
[TBL] [Abstract][Full Text] [Related]
9. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
[TBL] [Abstract][Full Text] [Related]
10. Chronobiological circadian aspects of serum lactate dehydrogenase and serum thymidine kinase in monitoring multiple myeloma.
Pasqualetti P; Casale R; Collacciani A
Am J Hematol; 1996 Feb; 51(2):176-7. PubMed ID: 8579069
[No Abstract] [Full Text] [Related]
11. Lactate dehydrogenase and its isoenzymes in serum from patients with multiple myeloma.
Copur S; Kus S; Kars A; Renda N; Tekuzman G; Firat D
Clin Chem; 1989 Sep; 35(9):1968-70. PubMed ID: 2776328
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma.
Simonsson B; Brenning G; Källander C; Ahre A
Eur J Clin Invest; 1987 Aug; 17(4):336-9. PubMed ID: 3117570
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
